- Home
- CMBM vs BLRX Comparison
CMBM vs BLRX Comparison
Compare CMBM & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMBM
- BLRX
- Stock Information
- Founded
- CMBM 2011
- BLRX 2003
- Country
- CMBM United States
- BLRX Israel
- Employees
- CMBM N/A
- BLRX N/A
- Industry
- CMBM Radio And Television Broadcasting And Communications Equipment
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- CMBM Technology
- BLRX Health Care
- Exchange
- CMBM Nasdaq
- BLRX Nasdaq
- Market Cap
- CMBM 26.5M
- BLRX 36.0M
- IPO Year
- CMBM 2019
- BLRX 2011
- Fundamental
- Price
- CMBM $0.72
- BLRX $0.20
- Analyst Decision
- CMBM Strong Buy
- BLRX Strong Buy
- Analyst Count
- CMBM 3
- BLRX 2
- Target Price
- CMBM $5.50
- BLRX $5.50
- AVG Volume (30 Days)
- CMBM 176.8K
- BLRX 1.7M
- Earning Date
- CMBM 02-13-2025
- BLRX 11-25-2024
- Dividend Yield
- CMBM N/A
- BLRX N/A
- EPS Growth
- CMBM N/A
- BLRX N/A
- EPS
- CMBM N/A
- BLRX N/A
- Revenue
- CMBM $172,215,000.00
- BLRX $21,991,000.00
- Revenue This Year
- CMBM N/A
- BLRX N/A
- Revenue Next Year
- CMBM $16.49
- BLRX N/A
- P/E Ratio
- CMBM N/A
- BLRX N/A
- Revenue Growth
- CMBM N/A
- BLRX N/A
- 52 Week Low
- CMBM $0.66
- BLRX $0.19
- 52 Week High
- CMBM $6.50
- BLRX $1.68
- Technical
- Relative Strength Index (RSI)
- CMBM 29.36
- BLRX 25.94
- Support Level
- CMBM $0.68
- BLRX $0.23
- Resistance Level
- CMBM $0.81
- BLRX $0.56
- Average True Range (ATR)
- CMBM 0.11
- BLRX 0.03
- MACD
- CMBM -0.03
- BLRX 0.00
- Stochastic Oscillator
- CMBM 10.79
- BLRX 11.82
About CMBM Cambium Networks Corporation
Cambium Networks Corp provides wireless broadband networking infrastructure solutions for network operators, including medium-sized wireless Internet service providers, enterprises, and government agencies. The company geographically operates in North America; Europe, Middle East and Africa; Caribbean and Latin America; and Asia Pacific. It derives maximum revenue from North America.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.